Cost-Effectiveness of Endovascular vs Open Surgery for Chronic Limb-Threatening Ischemia
JAMA Network Open · 2026
DOI: 10.1001/jamanetworkopen.2026.27335 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA Network Open, 2026. Verfasst von Zafar Zafari und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of Maryland Institute for Health Computing, Bethesda. Hauptthemen laut MEDLINE: Endovascular Procedures, Chronic Limb-Threatening Ischemia, Ischemia, Vascular Surgical Procedures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Choosing between endovascular and open (bypass) surgical revascularization for chronic limb-threatening ischemia has major implications for clinical practice.
Objective
To evaluate the cost-effectiveness of endovascular vs bypass surgical revascularization. Design, Setting, and Participants This economic evaluation used individual-level data from the Best Endovascular vs Best Surgical Therapy for Patients With Chronic Limb Ischemia (BEST-CLI) trial, with the first patient enrolled August 28, 2014, and the final October 18, 2019, for a median follow-up of 2.7 years. An individual-level, continuous-time Markov model with health states based on adjudicated clinical events from BEST-CLI was developed. Rates of clinical outcomes, health utilities, and health care resource use were derived from trial data. Unit costs came from Medicare insurance claims data and the physician fee schedule. The data were analyzed between June 27, 2025, and May 28, 2026. Main Outcomes and Measures The main outcomes were incremental cost per life-years gained, incremental quality-adjusted life-years (QALYs) gained, incremental net monetary benefit, and cost per major events of revascularization and amputation avoided over a 5- and 10-year time horizon. One-way and probabilistic sensitivity analyses were performed to quantify uncertainty.
Results
The cohort included 1434 patients from BEST-CLI (mean [SD] age, 67 [10] years; 1026 male [71.5%]). In the base case analysis, over a 5-year time horizon, the mean per-person direct medical costs were $118 559 (95% credible interval [CrI], $86 978-$157 152) for bypass surgery and $125 535 (95% CrI, $96 205-$160 357) for endovascular surgery. The mean survival per person was 3.84 years (95% CrI, 3.74-3.93 years) and 3.78 years (95% CrI, 3.61-3.94 years) for bypass and endovascular surgery, respectively. The mean QALYs per person were 2.53 (95% CrI, 2.34-2.70) for bypass surgery and 2.48 (95% CrI, 2.28-2.67) for endovascular surgery. Bypass surgery dominated endovascular surgery with respect to both costs per life-year and per QALY gained. The results over 10 years were consistent with those of the 5-year BEST-CLI follow-up. In the Monte Carlo simulation, there was a 93% chance that bypass surgery was more cost-effective than endovascular surgery. Conclusions and Relevance This cost-effectiveness study found that bypass surgery was more cost-effective in most probabilistic simulations; however, uncertainty remained, highlighting the need for future research to identify subgroups in whom each approach may be cost-effective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- University of Maryland Institute for Health Computing, Bethesda.
- Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore.
- Medidata Solutions, Boston, Massachusetts.
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Heart and Vascular Center, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
- Division of Vascular and Endovascular Surgery, University of California, San Francisco.
Zitieren
APA
Zafari, Z., Najafzadeh, M., Mahesri, M., Shin, H., Goodney, P. P., Conte, M. S., Creager, M. A., Dake, M. D., Kaufman, J. A., Powell, R. J., White, C. J., Strong, M. B., Rosenfield, K., Farber, A., Menard, M. T., & Choudhry, N. K. (2026). Cost-Effectiveness of Endovascular vs Open Surgery for Chronic Limb-Threatening Ischemia. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.27335
Vancouver
Zafari Z, Najafzadeh M, Mahesri M, Shin H, Goodney PP, Conte MS, et al. Cost-Effectiveness of Endovascular vs Open Surgery for Chronic Limb-Threatening Ischemia. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.27335
BibTeX
@article{Zafari2026,
author = {Zafari, Zafar and Najafzadeh, Mehdi and Mahesri, Mufaddal and Shin, HoJin and Goodney, Philip P and Conte, Michael S and Creager, Mark A and Dake, Michael D and Kaufman, John A and Powell, Richard J and White, Chris J and Strong, Michael B and Rosenfield, Kenneth and Farber, Alik and Menard, Matthew T and Choudhry, Niteesh K},
title = {Cost-Effectiveness of Endovascular vs Open Surgery for Chronic Limb-Threatening Ischemia},
journal = {JAMA Network Open},
year = {2026},
doi = {10.1001/jamanetworkopen.2026.27335}
}
EUVIMED